PDS Biotech reports Q1 net loss of $9.7M; plans Phase 3 trial for PDS0101 in Q4 2023

PDS Biotechnology Corp

2023-Q1 EPS reported -$0.32

Q1 net loss $9.7M ($0.32/sh) vs $8.5M ($0.32/sh) in Q1 2022; R&D spend rose to $5.8M.
Cash $65.2M at March 31, 2023; expected to fund operations into Q3 2024.
VERSATILE-002 Phase 2 data to be presented at ASCO 2023; Phase 3 VERSATILE-003 initiation planned for Q4 2023.
Received $1.4M from sale of NJ tax benefits; NCI-led triple combination trial progressing.
Preclinical Infectimune data showing flu protection published in peer-reviewed journal.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PDS Biotechnology Corp reported the three months ended March 31, 2023 results: net income approximately $9.7 million, EPS $0.32 per basic share and diluted share.

Period: the three months ended March 31, 2023
Net income: approximately $9.7 million
EPS: $0.32 per basic share and diluted share
Result: reported results

Exact text from the filing

Reported net loss was approximately $9.7 million, or $0.32 per basic share and diluted share, for the three months ended March 31, 2023

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

PDS Biotechnology Corp filing history →

Source: SEC EDGAR

accession 0001140361-23-024496

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.